Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...

Researchers plan to begin the first patient trial in 2027 thanks to promising preclinical results from a gene therapy ...

The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...

Karmanos 1st debut novel gene therapy offers a one-time treatment for adult hemophilia B, reducing the need for routine factor IX infusions.

CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...

Five-month-old Ginny was diagnosed with a rare genetic disorder called Spinal Muscular Atrophy, which she could die from ...

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...

Global stockout halts access to Hemgenix gene therapy, delaying treatment for adults with hemophilia B amid manufacturing ...

ABU DHABI, 23rd March, 2026 (WAM) -- The Department of Health – Abu Dhabi has announced the launch and funding of a UAE-first clinical trial for a novel gene therapy for MerTK-related retinitis ...

Ocugen, Inc. ('Ocugen” or the 'Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...

It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...